People news from the 10/24/06 News Brief

MANUFACTURERS Teva Pharmaceutical announced that Israel Makov plans to retire as CEO in 2007. Shlomo Yanai will join as CEO designate during the first part of 2007. AGENCIES Fission Communications has promoted Nancy Hausman from account manager to account supervisor, client services. In her new role, Nancy will continue to spearhead initiatives for several key Fission clients, including AstraZeneca, Cephalon, Merck, and Takeda. Medical Broadcasting Company (MBC) has hired Michael du Toit as SVP, management supervisor. His primary role will be to provide strategic counsel and manage the company's relationship with a major pharmaceutical firm client, MBC said. Previously, he was VP, client services and business development at TMX Communications in Philadelphia. He has also worked as the EVP at Ventiv Health, VP of marketing at GlaxoWellcome and as group account supervisor for BBD&O. AbelsonTaylor has announced the following new hires and promotions. Sarah Jenkins has been promoted from account executive to senior account executive, working on products in the insomnia drugs category. Nina Brakel joined the agency as senior account executive, providing support for two diabetes drugs. Lauren Claytor has been promoted from assistant account executive to account executive, working on accounts in the diabetes category. Jayme Fogel has been promoted from assistant account executive to account executive, working in the insomnia drugs category.   MEDIA Wendy Raupers has joined Lebhar-Friedman division Dowden Health Media as sales director of special programs for the professional division. Raupers joins from Advanstar where she held a number of titles, including associate publisher of RN magazine, and senior account manager on Medical Economics.  
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.